CD274 and breast cancer: Meanwhile, a specific anti-PD-L1 antibody agent might suppress the expression of soluble PD-L1 and remove its blocking effect on the PD-1 negative signaling pathway, leading to improving T cell viability and enhancing the killing of BC cells [47].